Get to know our clinical trials

Clinical trial of EGL-001 in adult patients with certain advanced and/or metastatic solid tumors

THE PRIMARY OBJECTIVE OF THIS STUDY IS TO ASSESS THE SAFETY AND TOLERABILITY OF EGL-001 IN PARTICIPANTS WITH CERTAIN ADVANCED AND/OR METASTATIC SOLID TUMORS THAT HAVE SHOWN PROGRESSION AFTER PREVIOUSLY BENEFITING FROM STANDARD TREATMENT WITH AN IMMUNE CHECKPOINT INHIBITOR

Imagen de la Dra. Ana Landa Magdalena, especialista en Oncología Médica de la Clínica Universidad de Navarra. La Dra. Landa se dedica preferencialmente a los ensayos clínicos y tumores de páncreas y vía biliar.
Dr. Ana Landa Magdalena [SP] Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Gastrointestinal Cancer Area
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE I/II FIRST-IN-HUMAN CLINICAL TRIAL OF EGL-001 IN ADULT PATIENTS WITH CERTAIN ADVANCED AND/OR METASTATIC SOLID TUMORS
  • Code EudraCT: 2024-512921-10-00
  • Protocol number: EGL-121
  • Promoter: EGLE Therapeutics
  • Molecule/Drug: EGL-001

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Read more about this clinical trial
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION